OncoMatch/Clinical Trials/NCT06817161

Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

Is NCT06817161 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies transcutaneous auricular vagus nerve stimulation for ovarian carcinoma.

Phase 3RecruitingCentre Francois BaclesseNCT06817161Data as of May 2026

Treatment: transcutaneous auricular vagus nerve stimulation — Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage IIB, III, IIIC, IV (FIGO)

FIGO stage ≥ IIB

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify